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ABSTRACT 
Objective: The main purpose of the study was to develop niosomal in situ gel of prednisolone sodium phosphate (PSP) with increased 
bioavailability (enhanced permeation) and sustained action (drug retention at the target site). 
Methods: Using different ratios of span 60 and cholesterol (chol), niosomes were prepared by thin film hydration method and optimized by 
evaluating different parameters like drug content, entrapment efficiency, particle size and in vitro drug diffusion study. The niosomal pellets were 
further incorporated in in situ gel, prepared by the cold method and further optimized by parameters like gelling parameters, mucoadhesive 
strength and in vitro, in vivo drug release study.  
Results: The optimized niosomal formulation containing span 60 and chol in equal proportion (1:1) showed better drug content (DC) i.e. 
86.3±0.39% and entrapment efficiency (EE) i.e. 83.4±0.22 with vesicle size of 465±0.24 nm. The in vitro drug diffusion study indicated t90 value of 
490 min thus proving sustained action of the formulation. The optimized in situ gel containing poloxamer 407 (P407) and poloxamer 188 (P188) in 
the ratio of 1:2.7 showed gelation temperature at 37 ⁰C (physiological temperature of the body) and t90 value of 10 h thus depicting sustained 
action. The increased area under curve (AUC) value by 1.75 folds proved increased bioavailability of the drug.  
Conclusion: Thus sustained drug delivery with increased bioavailability was designed for prednisolone sodium phosphate for the treatment of 
ocular inflammation. 
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Poor bioavailability of ocularly administered drug can be attributed 
to factors which include tear dynamics (blinking reflex and tear 
turnover) [1], non-productive absorption, transient residence time 
in the cul-de-sac, relative impermeability through corneal epithelial 
membrane, rapid precorneal elimination, drainage by gravity, 
frequent installation, enzymatic metabolism, nasolacrimal drainage, 
and the absence of controlled release [2-8]. Due to these 
physiological and anatomical constraints, a very small fraction of the 
administered drug (approx.1% or even less) of the instilled dose is 
available for ocular absorption [9-10]. Frequent dosing of drugs thus 
becomes a necessity to achieve the therapeutic concentration at the 
targeted site. This often results in the corresponding increase in local 
and systemic side effects. The high dose and dosing frequency cause 
unavoidable systemic side effects like stomach upset and disturbed GI 
motility [11]. The systemic route can overcome this but due to the 
presence of the blood-aqueous barrier and blood-retinal barrier, it 
ultimately leads to high loading dose at the target site. Various 
approaches, like viscosity enhancement, use of mucoadhesive, 
particulate drug delivery, vesicular drug delivery, prodrugs, and other 
controlled systems like ocuserts, iontophoresis, bioadhesive gels, 
ocular insert, contact lenses etc. are being explored [3,12-14].  
Vesicular systems (niosomes and liposomes) can act as drug 
reservoirs. Niosomes offers advantages like no variation in the 
purity of surfactants, cost-effective, chemically stable, low toxicity 
because of their non-ionic nature, flexibility in the structure which 
helps them to form micelles and can improve the performance of the 
drug via better availability and controlled delivery at a particular 
site. Niosomes are capable of encapsulating both hydrophilic and 
lipophilic drugs and can serve as effective drug carriers [15]. 
However, nonionic surfactant vesicles may promote drug absorption 
by preferentially modifying the permeability characteristics of the 
conjunctival and scleral membranes as surfactants in lower 
concentration are used as penetration enhancers [16, 17]. 
The in-situ gel is drug delivery system that is in sol form before 
administration in the body, but undergo gelation with the change in 
physiological conditions, to form sol to gel (from the lat. gelu—
freezing, cold, ice or gelatus—frozen, immobile). Vesicular systems 
in combination with mucoadhesive polymers show a controlled as 
well as a prolonged effect [18, 19]. Prolonging the drug contact time 
with the surface of the eye can also increase their penetration 
through the cornea, hence increasing the accessibility of the drug to 
aqueous humor [20-22]. This can be accomplished by use of 
bioadhesive polymer which helps the drug to remain adhered to eye 
surface by forming a noncovalent bond for a long period of time thus 
preventing the drug from undergoing nasolachrymal drainage. This 
will reduce the amount of drug (dose of the drug) and the dose 
frequency necessary for therapeutic effect. A reduction in dose will 
help to reduce the incidence of systemic side-effects. 
PSP is corticosteroid drug effective in the treatment of steroid 
responsive inflammatory conditions such as allergic conjunctivitis, 
acne rosacea, superficial punctate keratitis, herpes zoster keratitis, 
iritis, cyclitis etc. PSP decreases inflammation by suppressing 
migration of polymorphonuclear leukocytes and reversing 
increasing capillary permeability for the treatment [23]. The major 
drawback of steroid treatment is the side effects associated with it if 
used over a long period of time. 
The aim of the present investigation was to achieve the increased 
permeation of PSP by loading in niosome vesicles and improve its 
retention time at the particular site of action by incorporating the 
drug-loaded niosome into in situ gel which significantly reduces 
dosage frequency hence increase patient compliance.  
MATERIALS AND METHODS 
Materials 
PSP was obtained from Sai Life Sciences, Pune. Span 60 from Loba 
chemicals, chol from Analab fine chemicals, P407and P188 from 
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BASF Chemicals were procured. All the chemicals used were of 
analytical grade. 
Preparation of niosomes 
Ethanol injection method 
Niosomes containing PSP was prepared by modified ethanol 
injection method. Surfactant and chol in different ratios were 
dissolved in methanol. The resulting solution was slowly injected 
using microsyringe at a rate of 0.25 ml/min into 15 ml of Phosphate 
buffer (PBS) pH 7.4 containing PSP. The solution was stirred 
continuously on a magnetic stirrer (Remi, 2MLH) and the 
temperature was maintained above 60 °C. Stirring continued for 1-
1.5 h. Vaporization of solvent takes place, resulting in spontaneous 
vesiculation and formation of unilamellar spherical niosomes [24]. 
Thin film hydration 
Accurately weighed quantity of surfactant and chol in different 
molar ratios (table 1) were dissolved in chloroform and methanol 
mixture in a round bottom flask. The solvent mixture was 
evaporated in a rotary flash evaporator (Trident labotech, Thane) 
under a vacuum of 20 inches of Hg at a temperature of 25±2 °C and 
the flask rotated at 100 rpm until a smooth, dry lipid film was 
obtained. The film was hydrated with 10 ml of PBS pH 7.4 containing 
25 mg prednisolone sodium phosphate drug for 45 min at 60 °C with 
gentle shaking on a water bath. The niosomal suspension was 
further stored at 2-8 °C for 24 h [24]. 
Batches of niosomes were prepared to vary in the method of 
preparation (table 1), the combination of surfactants (table 2), an 
individual surfactant in different concentrations (table 3), selection 
of surfactant grade (table 4) and the ratio of chol and span 60 (table 
5) respectively. Optimization was carried out on the basis of DC, EE, 
vesicle size and in vitro drug diffusion study. 
Preparation of niosomal in situ gel 
The ‘‘Cold method’’ was adopted for preparing poloxamer-based 
gels. The required amounts of P407 and P188 for each formulation 
were carefully weighed and placed in a flat bottomed vial. After the 
addition of the required amount of 0.9% NaCl solution for 
isotonicity, the vial was placed at 4 ⁰C until P407 and P188 were 
dissolved completely and a clear solution was obtained. In the study, 
P407 and P188 concentrations in sols or gels were expressed as the 
weight percentage (% w/v). The equivalent amount of niosomal 
pellets obtained from the freeze-drying process was added into the 
gel formulation along with 100 mg of the synthesized polymer [25] 
and benzalkonium chloride (0.01%) to form final formulation of 
niosomal in situ gel. Preliminary blank batches were prepared 
without niosomes and bioadhesive polymer to find out the ratio of 
P407 and P188 exhibiting gelation temperature near to 37 ⁰C [26]. 
Evaluation of niosomes 
Drug content 
In 1 ml of niosomal buffer solution, 2 ml methanol was added and 
further volume was made up by distilled water. Addition of 
methanol cause breakdown of niosomes and hence drug could freely 
get dissolve in a solvent. Each of this solution was further diluted 
according to the requirement by distilled water. Absorbance was 
measured on UV-visible spectrophotometer (Shimatzo UV visible 
1650, Japan) at 247 nm [24]. Drug content was determined by using 
the formula 
Percent drug conten =
Test abs.× Standard Conc.
Standard abs.× weight of drug
× Dilution factor × 100
 
Table 1: Composition of trial batches for method selection 
Batch code M1 M2 M3 M4 M5 M6 M7 
Chol (mg) 25  25  25 25 25 25 - 
Span 60 (mg) 25  - - 25 - - - 
Tween 20 (mg) - 25  - - 25 - - 
Tween 80 (mg) - - 25 - - 25 - 
Span 80 (mg) - - - - - - 25 
Methanol (ml) 1  1  1 1 1 1 1 
CHCl3 4  (ml) 4  4 4 4 4 4 
Drug (mg) 25  25  25 25 25 25 25 
Buffer (ml) 7.5  7.5  7.5 7.5 7.5 7.5 7.5 
Technique Ethanol injection method Thin film hydration technique 
 
Table 2: Composition of trial batches for combination surfactants 
Batches C1 C2 C3 C4 C5 C6 
Chol (mg) 25 25 25 - - - 
Span 60 (mg) 12.5 - - 12.5 12.5 - 
Span 80 (mg) 12.5 12.5 - - - 12.5 
Tween 20 (mg) - 12.5 12.5 12.5 - - 
Tween 80 (mg) - - 12.5 - 12.5 12.5 
Methanol (ml) 1 1 1 1 1 1 
CHCl3 4 (ml) 4 4 4 4 4 
Drug (mg) 25 25 25 25 25 25 
Buffer (ml) 7.5 7.5 7.5 7.5 7.5 7.5 
 
Table 3: Composition of trial batches for shortlisting surfactant 
 S1 S2 S3 S4 
Chol (mg) 25 25 25 - 
Span 60 (mg) 25 - - - 
Tween 20 (mg) - 25 - - 
Tween 80 (mg) - - 25 - 
Span 80 (mg) - - - 25 
Methanol (ml) 1 1 1 1 
CHCl3 4 (ml) 4 4 4 
Drug (mg) 25 25 25 25 
Buffer (ml) 7.5 7.5 7.5 7.5 
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Table 4: Composition of trial batches for selection of surfactant grade 
Batches CS1 CS2 CS3 CS4 CS5 CSS1 CSS2 CSS3 CSS4 CSS5 
Chol (mg) 25 25 25 25 25 25 25 25 25 25 
Span 60 (mg) 25 50 75 100 125 - - - - - 
Span 80 (mg) - - - - - 25 50 75 100 125 
Methanol (ml) 1 1 1 1 1 1 1 1 1 1 
CHCl3 4 (ml) 4 4 4 4 4 4 4 4 4 
Drug (mg) 25 25 25 25 25 25 25 25 25 25 
Buffer (ml) 10 10 10 10 10 10 10 10 10 10 
Chol: surfactant ratio 1:1 1:2 1:3 1:4 1:5 1:1 1:2 1:3 1:4 1:5 
 
Table 5: Composition of trial batches for selection of ratio between chol and surfactant 
Batches CS6 CS7 CS8 CS9 CS10 CS11 CS12 CS13 CS14 CS15 CS16 CS17 
Chol (mg) 25 25 25 25 25 50 62.5 75 87.5 150 200 250 
Span 60 (mg) 150 175 200 225 250 25 25 25 25 150 200 250 
Methanol (ml) 1 1 1 1 1 1 1 1 1 1 1 1 
CHCl3 4 (ml) 4 4 4 4 4 4 4 4 4 4 4 
Drug (mg) 25 25 25 25 25 25 25 25 25 25 25 25 
Buffer (ml) 10 10 10 10 10 10 10 10 10 10 10 10 
Chol: Surfactant ratio 1:6 1:7 1:8 1:9 1:10 2:1 2.5:1 3:1 3.5:1 1:1 1:1 1:1 
 
Entrapment efficiency 
Prepared PSP niosomes were separated from the unentrapped drug 
by centrifugation at 2750 rpm for 60 min using the cooling 
centrifuge. Cooling centrifuge (Laby instruments, India) was used as 
niosomes are stable and stored at the refrigerated condition that is 
at 2-8 ⁰C. The absorbance of the supernatant was taken after 
appropriate dilution at 247 nm. Settled pellets were dispersed in 
distilled water to get a clear solution. After appropriate dilutions, 
absorbance was recorded [27]. The entrapment efficiency was 
calculated through the following relationship,  
% EE =
Entrapped drug
Entrapped drug + Drug in supernatant
× 100 
Vesicle size distribution  
The average vesicle size of niosomes was measured by the method 
of laser light diffraction using Nanophox NX0088. Prior to 
measurements, about 50 mg of each sample was dispersed with 100 
ml of hexane and signal to noise ratio was measured in order to 
eliminate error if any. The vesicle size distributions were estimated 
by setting the intensity of the scattered light at a wavelength of 750 
nm and the scattering angle (θ) of 90 [26]. 
In vitro release study 
Drug release from niosomes was studied using a dialysis method. 
Dialysis bags were soaked before use in distilled water at room 
temperature for 12 h to remove the preservative, followed by 
rinsing thoroughly in distilled water. In vitro release of PSP from 
niosomes was conducted by dialysis in a dialysis sac made up of a 
cellophane membrane (Sigma-Aldrich) with 100 ml of PBS (pH 7.4) 
at 37 °C. Two ends of the dialysis sac were tightly bound with 
threads. The sac was hung inside a beaker with the help of a glass 
rod so that the portion of the dialysis sac with the formulation 
dipped into the buffer solution. The beaker was kept on a magnetic 
stirrer (Remi, 2MLH) and stirring was maintained at 100 rpm at 37 
°C with thermostatic control. Samples were collected every at 15 
min, 30 min, 45 min, 1 h, 2 h, 3 h and further 1hr interval over a 
period of 6 h and assayed spectrophotometrically for drug released 
and the sampled volume of buffer maintained at the same 
temperature. An equal volume of fresh release medium was replaced 
at the same time intervals. The diffusion data were analyzed for 
calculating the amount of drug released and percentage drug 
released at different time intervals [25]. 
Release kinetics of drug 
The kinetics of the drug release was evaluated by the model fitting 
method using PCP Disso v3 software and the model with the highest 
correlation coefficient amongst them was considered to be the best 
model for the particular formulation 
Fourier transform infrared spectroscopy (FTIR) 
The infrared spectrum of prednisolone sodium phosphate was 
determined on Fourier Transform Infrared Spectrophotometer 
(FT/IR 4100, Jasco) using potassium bromide (KBr) dispersion 
method. The baseline correction was done using dried KBr. The 
samples to be analyzed and KBr were previously dried in the oven 
for 30 min and mixed thoroughly in 1:300 (sample: KBr) ratio in a 
glass mortar. These samples were then placed in a sample holder 
and scans were obtained at a resolution of 2 cm-1 from 4000 to 400 
cm-1
Differential scanning calorimetry (DSC) 
[28]. 
DSC measurements were performed on a differential scanning 
calorimeter containing an intra-cooler (DSC Mettler STAR SW 9.20, 
Switzerland). Nitrogen gas was purged (50 ml/min) to maintain an 
inert atmosphere. All accurately weighed samples (about 5-10 mg of 
samples) were placed in a sealed aluminum pan, and the samples 
were heated under nitrogen gas flow (20 ml/min) at a scanning rate 
of 10 °C per min from 40 to 340 °C. An empty aluminum pan was 
used as reference [29]. 
Optical microscopy 
Optical microscopy of the drug sample was carried out by using a Digital 
Microscope (Motic). A very slight quantity of the niosomal sample 
solution was spread on the glass slide. This slide was focused under 
various magnification lenses and the images were captured [30]. 
Zeta potential determination 
Niosomal dispersion (0.5 ml) was diluted to 50 ml with distilled 
water in a glass beaker with constant stirring. Zeta-potential of the 
resulting suspension was determined using the Zetasizer (model: 
Nano ZS, Malvern Instruments, Westborough, MA, USA) 
Electrophoretic mobility (μm/s) was measured using small volume 
disposable zeta cell and converted to zeta potential by inbuilt 
software using Helmholtz–Smoluchowski equation [26]. 
Polydispersity index (PDI) 
The PDI determination was using photon correlation spectroscopy 
with in-built Zetasizer (model: Nano ZS, Malvern Instruments, 
Westborough, MA, USA) at 633 nm [26]. The polydispersity index 
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Transmission electron microscopy (TEM) analysis 
TEM (Philips CM 200 super twin stem microscope) was used to 
determine the morphology of the niosomal vesicles. Few drops of 
the optimized niosomal formulation (CS17) were deposited on a 
carbon-coated copper grid and examined under a transmission 
electron microscope [31]. 
Evaluation parameters in situ gel 
Appearance 
The appearance of the gels was examined for clarity. The clarity of 
various formulations was evaluated by visual inspection under the 
black and white background. 
pH 
The pH of each formulation was examined using a digital pH meter 
(Equip tronics, EQ610). The pH meter was first calibrated using 
buffer solutions of pH 4 and pH 7. Then gel was taken in a beaker 
and the pH was measured [24]. 
Drug content of in situ gel 
In this study, each formulation (1 ml) was taken in a 100 ml 
volumetric flasks diluted with distilled water up to the mark. After 
suitable dilutions, the amount of drug was measured in the 
formulation by using ultraviolet spectroscopy at 246 nm [24].  
Gelation time 
The Tsol–gel of the formulation was determined by test tube 
inversion method. Niosomal in situ gel (2 ml) was transferred to a 
test tube and sealed with paraffin. This test tube was placed in the 
constant temperature water bath at 35±1 ⁰
Gel strength 
C. The sample was 
examined for gelation [24].  
Gelation temperature and gel melting temperature 
The Tsol–gel of the formulation was determined by test tube 
inversion method. Niosomal in situ gel (2 ml) was transferred to 
a test tube and sealed with paraffin. This test tube was placed in 
the constant temperature water bath (Equitron). The 
temperature of the water bath was increased in increments of 2 
⁰C and left to equilibrate at each new temperature. However, in 
the region of Tsol–gel temperature was raised slowly in the 
increments of 0.5 ⁰C. The formulation was examined for gelation 
which was said to have occurred when the meniscus would no 
longer move upon tilting through 90⁰. Measurements were done 
in triplicate [32].  
The obtained temperature is said to be T1. After attaining the 
temperature T1, further heating of gel causes liquefaction of gel and 
form the viscous liquid and it starts flowing, this temperature is 
noted as T2 i.e. gel melting temperature.  
Gelling capacity 
Determination of in vitro gelling capacity was done by a visual 
method. Colored solutions (1% Congo red solution in water) of in-
situ gel were prepared. The in vitro gelling capacity of prepared 
formulations was measured by placing 5 ml of the gelation solution 
(pH 7.4 PBS) in a glass test tube and maintained at 37±1 °C 
temperature. One ml of colored formulation solution was added with 
the help of pipette. As the colored solution comes in contact with 
gelation solution, it was immediately converted into the stiff gel-like 
structure. The gelling capacity of the solution was evaluated on the 
basis of the stiffness of the formed gel and time period for which the 
formed gel remains as such. The in vitro gelling capacity was graded 
in two categories on the basis of gelation time and time period for 
which the formed gel remains as such [33]. 
Texture analysis 
Texture analysis of the prepared gel formulation was done by using 
Brookefield texture analyzer CT3. The formulations were evaluated 
for the following parameters. 
The gel strength, which is an indication of the viscosity of the gel at 
physiological temperature, was measured by measuring the force 
required for depression of gel at 37 ⁰C temperature [32].  
Mucoadhesive strength 
The mucoadhesive potential of each formulation was determined by 
measuring a force required to detach the formulation from the 
conjunctival membrane. The mucoadhesive force expressed as the 
detachment stress in dynes/cm2 was determined from the minimum 
weight that detached the mucosal tissue from the surface of each 
formulation [34, 35]. 





m = Weight required for detachment in g 
g = acceleration due to gravity (980 cm/s2) 
A = area of mucosa exposed (cm2
In vitro drug diffusion study 
) 
Spreadability 
The spreadability was evaluated by measuring the distance to which 
the 10 ml formulation would spread under the influence of specified 
force applied on gel [24]. 
Viscosity measurement 
The viscosity of prepared gel formulation was measured by using 
Brookefield DV-II pro-plus viscometer (Brookefield engineering 
Labs Inc. Middleboro, USA) equipped with a helipath stand and T bar 
spindles. Viscosity measurements were made at variable 
temperature and variable shear rate. For temperature dependent 
study, the formulation was subjected to constant shear rate at 
different temperatures from 25 to 40 ⁰C. During this testing, the 
temperature was raised gradually by 1 ⁰C and the viscosity of the 
sample was measured after attaining the set temperature. 
Measurements were done in triplicate. Steady shear sweep test was 
carried out by measuring the viscosity at the constant temperature 
of 25 ⁰C and 37 ⁰C but varying the rotation speed of the spindle from 
10 to 100 rpm [32].  
In vitro release studies were carried out using Franz diffusion cell 
and the temperature was adjusted to 37±0.5 ⁰C. The prehydrated 
dialysis membrane (cellophane membrane) was used for the study. 
Samples were withdrawn at periodic intervals of 0.5,1,2,3,5 and 6 h 
and replaced with fresh simulated tear fluid to maintain sink 
conditions. The drug content was analyzed using UV-Visible 
Spectrophotometer at 247 nm using simulated tear fluid as blank 
[25]. The apparent diffusion coefficient was calculated by using 
formula  
Dapp =  
∆Q
∆t




Where ΔQ/Δt (μg/min) is the flux across the corneal tissue. A is the 
area of diffusion (cm2), Co (μg/cm3) is the initial concentration of 
drug in the donor compartment, and 60 is taken as the factor to 
convert min into second. The flux across the cornea was obtained 
from the slope of the regression line obtained from the linear part of 
the curve between the amount permeated (Q) vs time (t) plot. 
Ex vivo diffusion study 
Ex vivo drug diffused study was performed for the optimized 
formulation and marketed formulation by using 5 ml of Franz 
diffusion cells containing simulated tear fluid. The goat conjunctival 
epithelium was used for the study. 1 ml of sample was placed in the 
donor compartment and diffusion study was conducted for 6 h at 
37±1 ⁰C. Sample (0.5 ml) was withdrawn at 1/2 h for an hour and 
then every 1 h and the same quantity of simulated tear fluid was 
added [26]. 
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Primary skin irritation test 
Two healthy albino rabbits were used for the experiment. Animal 
husbandry was conducted in accordance with the "Guide for the 
Care and use of Laboratory Animals," National Institute of Health 
(NIH) publication No.85-23.  
Methods: The backs of the animals were cleaned free of fur with a 
razor at least 4 h before application of the sample. One ml sample of 
the least irritant polymer obtained from ex vivo test was then 
applied to the particular site to an area of skin approximately 1" × 1" 
(2.54 × 2.54 cm) square. The sample applied site was covered with a 
nonreactive tape. Animals were returned to their cages. After a 24 h 
exposure, the tape was removed and the test sites were wiped with 
tap water to remove the test sample. At 24 and 72 h after the test 
sample application, the test sites were examined for dermal 
reactions in accordance with the Federal Hazardous Substance Act 
(FHSA)-recommended Draize scoring criteria (Appendix 1). Primary 
Irritation Index (P. I. I.) of the test sample was calculated following 
test completion [36].  
In vivo draize eye irritation test 
The Draize test was performed on white albino rabbits. In this test 
100 μg test sample was placed into the lower cul-de-sac of rabbit’s 
right eye (1.5-2 kg, 13 w of age). The left eye was treated as a 
control. Rabbits’ eyes were observed periodically for redness, 
swelling and watering of the eye at 1 h, 4 h and every 24 h for 7 d. 
Three rabbits were used for the test substance. These parameters 
were calculated from the weighted score for each part of the rabbit eye 
such as (cornea, iris, and conjunctiva) and also from the sum of these 
scores. The maximal average Draize total scores (MAS) are classified 
into non-irritants (0<MAS<0.5), slight irritants (0.5<MAS<15), mild 
irritants (15<MAS<25), moderate irritants (25<MAS<50) and severe 
irritants (50<MAS) [37]. Approval of the institutional animal ethics 
committee (Approval No. MCP/IAEC/01/2016) was obtained prior to 
the commencing of the study from Modern College of Pharmacy, 
Nigdi, Pune. 
Pharmacokinetic study 
The drug pharmacokinetics in the aqueous humor on ocular 
instillation of the optimized formulation (B) and the drug solution 
was measured on male New Zealand albino rabbits. Rabbits (2–2.5 
kg) were kept in cages kept in a light-controlled (alternate night and 
day cycles, 12 h each) air-conditioned chamber under controlled 
humidity (45±5%). All the experimental protocols were approved by 
the Institutional Animal Ethics Committee (IAEC) of Modern College 
of Pharmacy, Nigdi, Pune constituted under the guidelines of 
Committee for the Purpose of Control and Supervision of 
Experiment on Animals (CPCSEA, India) with protocol approval 
number MCP/IAEC/01/2016. 
HPLC analysis of prednisolone sodium phosphate 
The quantitative determination of PSP pharmacokinetics in the 
rabbit aqueous humor was based on a previously validated HPLC 
method [31]. A reversed-phase HPLC-UV method was used to 
measure PSP in aqueous humor. The HPLC (Water 600) apparatus 
consisted of quaternary (gradient system), HPLC pump (isocratic) 
equipped with 30 w high resolution UV/Vis detector DATA ACE 
Chromatography Software (version 1.50) integrator software and a 
Grace smart RP C18 column (4.6 mm × 250 mm and 10 mm particle 
size). 
The mobile phase was prepared by mixing 2.5 ml of isopropanol 
with 0.2 ml of phosphoric acid and diluting with deionized water to 
90 ml. The pH was adjusted to 3.0 with 1 M NaOH and then diluted 
further to 100 ml. The mobile phase was degassed and filtered 
through 0.45-micron nylon filters. The flow rate of the mobile phase 
was set at 1 ml/min. The detector was set at 246 nm (absorption 
maxima of PSP). The injection volume was 20 μl; run time was 10 
min. The calibration concentration ranges for the standards were 
0.050 to1.0 μg/ml. An internal standard 6-alpha-methyl-
prednisolone was added to every standard and sample [38].  
Study design 
A two treatment, non-blind, randomized, parallel design was 
adopted to compare the drug pharmacokinetics in the rabbit 
aqueous humor following ocular instillation of the optimized 
niosomal in situ gel (B). Twelve rabbits were randomly divided into 
two groups. The niosomal in situ gel (B) was instilled (50 μl) in the 
lower conjunctival sac of the right eye of each rabbit belonging to 
the first group (Treatment A) while the same volume of the drug 
solution was applied to those of the second group (Treatment B). 
The rabbits were systemically anaesthetized with ketamine 
hydrochloride (intramuscular injection, 50 mg/kg). At 5 min 
intervals, the formulation was instilled into the eye using a 
micropipette. At 0.5, 1, 2, 4, and 8 h post-instillation, the rabbits 
were locally anaesthetized (benoxinate HCl, 0.4% w/v) and aqueous 
humor samples (0.15 ml) were withdrawn by anterior chamber 
paracentesis [39]. 
Aqueous humor samples were stored at −20 °C until HPLC analysis. 
Prior to HPLC analysis, the thawed aqueous humor samples were 
spiked with 6 alpha methylprednisolone. In order to precipitate the 
associated proteins, the spiked samples (0.1 ml) were vortex mixed 
(30 s) with acetonitrile (0.2 ml). Following centrifugation (15 min, 
12000 rpm), the drug content in the organic phase layer was 
determined by HPLC. 
Pharmacokinetic analysis 
The graph of concentration of prednisolone sodium phosphate 
(mean±SD) in the rabbit aqueous humor was plotted against time. 
The maximum drug concentration (Cmax, in μg/ml) and the time to 
reach Cmax (Tmax, in h) were directly obtained from the individual 
subject curves. The mean residence time (MRT, in h) was estimated 
using graph prism® software. The area under the aqueous humor 
concentration-time curve (AUC, in μg/h/ml) was calculated using 
the trapezoidal rule method. The results were statistically evaluated, 
using one-way ANOVA, at P<0.05. The increase in the ocular drug 
bioavailability (folds) was estimated by dividing the AUC of the 
niosomal in situ gel (B) over that of the drug solution. 
Sterility test 
The formulation was sterilized by membrane filtration method and 
was incubated with different culture media like soybean casein 
digest medium and fluid thioglycate medium for a period of 14 d and 
observed for the presence of microbial growth if any [33]. 
Stability study 
On the ICH, Harmonized Tripartite Guidelines on stability testing of 
new drug substance and product, fundamental recommendations 
are summarized.  
For the drug substances intended for storage in a refrigerator are 
given in table 6. 
 
Table 6: ICH guidelines for the drug substances intended for storage in a refrigerator. 
Study Storage condition  Time period  
Long term 5 °C±3 °C 12 mo 
Accelerated 25 °C±2 °C/60% RH±5% RH 6 mo 
 
In order to determine the stability of gels, the samples were kept in 
airtight glass vials packed by aluminum foil. The niosomal in situ 
gels were stored at 25 ⁰C±2 ⁰C/60%±5% RH for 6 mo [40]. These 
samples were evaluated for drug content, gelation temperature and 
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physical characteristics. Samples were also stored at 5 °C±3 °C for 3 
mo. These samples were also evaluated for drug content, gelation 
temperature, and physical characteristics. 
Statistical analysis 
The obtained data were analyzed using the one-way analysis of 
variance (ANOVA) test (P<0.05) was considered as an estimate of 
significance while evaluating the degree of difference between 
various formulations. 
RESULT AND DISCUSSION 
Optimization of niosomes on the basis of DC, EE and vesicle size 
Method selection 
 
Fig. 1: Graph of DC and EE of preliminary batches for method 
selection data expressed mean±SD (n=3) 
 
The niosomes were prepared by two methods namely thin film 
hydration and ethanol injection method. It was observed that the DC 
and EE of niosomes prepared by thin film hydration method were 
significantly (p<0.05) higher than of niosomes prepared by the 
ethanol injection method (fig. 1). In addition to this, niosomes were 
also evaluated on the basis of their morphology and appearance by 
motic digital microscopy. Niosomes prepared by thin film hydration 
technique were spherical and uniform in size. Hence thin film 
hydration technique was selected for niosomes preparation. Similar 
results were obtained in salbutamol sulphate liposomes preparation 
by Honmane SM et al. 2014, where entrapment efficiency was higher 
for liposomes prepared by thin film hydration technique. 
Combination of surfactants 
Niosomes were evaluated for the combined effect of surfactants. By 
preparing niosomes using a single surfactant and in combination, DC and 
EE were calculated (fig. 2). It was observed that the use of surfactants in 
combination did not show a significant effect on DC and EE. The drug 
content and encapsulation efficiency depended on the HLB value of the 
mixture of surfactants used. The higher HLB of the mixture of surfactants 
with respect to individual surfactant reduced its potential in solubilizing 
and thus entrapping the PSP molecule. The results coincide with the 
previous study by Taymouri S et al. 2016where effect of different 
surfactants on physical properties of carvedilol nanoniosomes was 
studied. Hence single surfactant niosomes were prepared instead of a 
combination to prevent interaction. 
 
Fig. 2: Graph of DC and EE of trial batches for the combination of 
surfactants data expressed mean±SD (n=3) 
 
Selection of surfactants 
 
Fig. 3: Graph of DC and EE of trial batches for selection of 
surfactants data expressed mean±SD (n=3) 
 
Four surfactants used during formulation were span 60, span 80, 
tween 20 and tween 80 to prepare niosomes. It was observed that 
use of spans showed significantly (p<0.05) higher DC and 
entrapment efficiency over tweens (fig. 3). The probable reason 
behind this is the Hydrophilic-Lipophilic Balance (HLB) value. HLB is 
a dimensionless parameter, which is the indication of the solubility 
of the surfactant molecule. Surfactants with HLB between 4 and 8 
can be used for the preparation of vesicle [41]. Hydrophilic 
surfactants with an HLB value ranging from 14 to 17 are not suitable 
to form a bilayer membrane due to their high aqueous solubility. 
However, with the addition of an optimum level of chol, niosomes 
are indeed formed from Tween 20 (HLB value = 16.7). Spans possess 
lower HLB which makes the drug entrapment of steroid drug moiety 
more efficient. The result was found to be in agreement with 
previous data reported by Shaji J et al. 2016 and Taymouri S et al. 
2016 which indicated that lower the HLB of the surfactant; the 
higher will be the entrapment efficiency. 
 
Selection of surfactant grade 
Table 7: DC, EE, and vesicle size for the selection of surfactant grade 
Batch code DC (%) EE (%)* Vesicle size (nm)* * 
CS1 60.16±0.12 72.4±0.23 423±0.03 
CS2 51.59±0.16 86.95±0.36 401±0.43 
CS3 57.98±0.47 86.06±0.41 494±0.52 
CS4 41.96±0.14 90±0.33 485±0.16 
CS5 59.33±0.05 91.54±0.16 469±0.38 
CSS1 54.4±0.27 87.19±0.36 356±0.26 
CSS2 61.29±0.62 91.31±0.22 407±0.14 
CSS3 42.12±0.29 80±0.43 396±0.49 
CSS4 43.47±0.32 62.33±0.62 404±0.04 
CSS5 55.57±0.38 81.61±0.04 375±0.55 
*(mean±SD, n=3) 
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As discussed in the selection of surfactant section, HLB value plays 
an important role in the formation of stable niosomes. The 
hydrophilic-lipophilic balance (HLB) system, which is a measure of 
the relative contributions of the hydrophilic and lipophilic regions of 
the surfactant molecules, is more commonly used as an indicator on 
potential niosomes formation. The HLB value of span 60 is 4.7 and 
HLB value of span 80 is 4.3 respectively. So considering the HLB 
value, Span 80 having lower HLB value compared to span 60 must 
be able to incorporate steroid moiety more efficiently than span 60. 
But there is an exception. Sorbitan monooleate (Span 80, HLB of 4.3) 
cannot assemble into niosomes (on their own) due to their 
inadequate geometry, hence packing properties. The oleate moiety 
of this surfactant molecule has a double bond (with relatively high 
electron density) at the C9 which repels adjacent hydrocarbon 
chains resulting in the characteristic “kink” in the structure [42]. 
Vesicle size of niosomal dispersion containing span 80 was less as 
compared to that of span 60 (table 7). This might be due to the 
increase in the hydrophobicity of the surfactant from Span 60 to 
Span 80. The decrease in surface free energy with increasing the 
hydrophobicity of surfactants may be the major attribute of 
reduction in the vesicle size of niosomes. Since the DC of niosomes 
obtained by using span 80 was significantly (p<0.05) less due to kink 
in the structure as compared to span 60, the span 60 was selected as 
surfactant. The results coincide with the previous study by Essa 
2010 where effect of formulation and processing variables on 
sorbitan monopalmitate niosomes was studied. 
 
Selection of chol: surfactant ratio 
 
Table 8: DC, EE and vesicle size for a selection of chol: surfactant ratio 
Batch code DC (%)* EE (%)* Vesicle size (nm)* 
CS6 64.6±0.12 63.9±0.16 324±0.05 
CS7 55.8±0.35 69.2±0.26 357±0.15 
CS8 66.5±0.41 70.9±0.38 373±0.22 
CS9 57±0.55 79.4±0.41 410±0.29 
CS10 56.3±0.26 73.2±0.64 428±0.45 
CS11 42.1±0.09 66.9±0.28 385±0.62 
CS12 68±0.034 70.1±0.36 448±0.54 
CS13 53.5±0.49 53.8±0.05 424±0.32 
CS14 68.5±0.54 61.4±0.19 401±0.41 
CS15 72.4±0.06 80±0.32 436±0.38 
CS16 78.1±0.42 80.7±0.46 417±0.61 
CS17 86.3±0.39 83.4±0.22 465±0.24 
*(mean±SD, n=3) 
 
In order to find the optimum concentration ratio of chol: surfactant, 
different batches of niosomes were prepared (table 8) ratio value 
(chol: span 60) ranged from 1 to 10. Reverse order of ratio (chol: 
span 60) from 2 to 3.5 was also used to prepare niosomes. The 
amount of chol to be added depends on the HLB value of the 
surfactants. As the HLB value increases above 10, it is necessary to 
increase the minimum amount of chol to be added in order to 
compensate for the larger head groups [43]. EE decreases as the 
HLB value decreases from 8.6 to 1.7. It was seen that the addition of 
chol enables more hydrophobic surfactants to form vesicles, 
suppresses the tendency of the surfactant to form aggregates, and 
provides greater stability to the lipid bilayer by promoting the gel-
liquid transition temperature of the vesicle [44]. The EE is affected 
by the phase transition temperature (Tc) of the surfactant. 
Thus Span 60 with a high Tc exhibits the highest EE. The 
encapsulation efficiency is improved when the chol content was 
increased to 50% molar ratio due to the reduction of drug 
permeability. A similar result was reported by Mokhtar et al. 2008, 
who studied the effect of some formulation parameters such as the 
chol content of niosomes on flurbiprofen encapsulation and release 
rates of niosomes prepared from proniosomes. The optimization of 
the niosomal batch was not possible only on the basis of DC and EE 
as prolong the effect of PSP was expected (fig. 4). Hence the batch 
was selected on the basis of in vitro drug release. 
 
 
Fig. 4: Graph of DC and EE of trial batches for selection of chol: surfactant ratio data expressed mean±SD (n=3) 
 
In vitro drug release 
In vitro dissolution of niosomal batches was carried out by dialysis 
bag method. The value of t90 played an important role in 
determining the optimized niosomal batch. Our main purpose of this 
study was to sustain the release of drug and hence t90 was expected 
to be higher for the optimized batch. The batch CS17 (chol: span 60 
ratio was 1) exhibited t90 of 490 min that is the release was 
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sustained upto 8 h of the drug by this formulation (fig. 5 and 6). The 
change in chol: span60 ratio did not showed linear correlation either 
with DC, EE or in vitro drug release. The values differed randomly 
without showing any correlation. The niosomal batches CS1, 
CS15,CS16, CS17 all contained chol: span 60 ratio 1 i.e. both the 
ingredients were in equal quantities but still there t90 values were 
variable viz 112 min, 370 min, 435 min and 490 min respectively 
(table 9). The difference in these batches was the change in 
concentration with respect to the whole composition. The amount of 
surfactant used in CS1 was ten times lesser than that used in CS17. 
Hence the value of t90 was shifted from 112 to 490 min. Surfactant 
concentrations were within the limits in accordance with safety 
guidelines where the concentration of surfactant does not exceed by 
1-2.5 % w/w. In batch CS17 the amount of span is 1% w/v. The 
primary function of surfactant is to improve the solubility of 
substance but PSP being water soluble, this function need not has 
to be achieved. The surfactants in higher concentrations act as 
sustained release polymers which cause the drug to release at the 
controlled rate. This was in agreement with findings of other studies 
like Tabbakhian M et. al 2006;Das k et. al 2011;Azeem A et. al 2008 
indicating a more sustained drug permeation and possibly a 
greater drug deposition and increased drug release where drug 




Fig. 5: Dissolution drug profile of batches CS1 to CS10data expressed mean±SD (n=3) 
 
 
Fig. 6: Dissolution drug profile of batches CS11 to CS17data expressed mean±SD (n=3) 
 
Release kinetics of drug 
The kinetics of the drug release was evaluated by model fitting 
method using PCP Disso v3 software and the model with the highest 
correlation coefficient amongst them was considered to be the best 
model for a particular formulation. 
Different t90 values were observed for different batches. The batch 
CS17 showed (chol: span 60–1:1) maximum t90 value of 491.9 min 
(table 9). This indicates that 90% drug release occurred in 490 min 
thus sustaining the release to upto 8 h. The kinetics of the drug 
release was evaluated by a model fitting method using PCP Disso v3 
software and the model with the highest correlation coefficient 
amongst them was considered to be the best model. The release 
kinetics indicated that the optimized batch (CS17) followed 
Korsmeyer Peppas kinetics where R is 0.9935, n is 0.4352 and k is 
5.846. The Korsemeyer Peppas release model equation is, F = (M 
t/M) = k m t n Where F = fraction of drug release at time t; Mt = 
amount of drug release at time t; M = total amount of drug in dosage 
form; K = constant. ‘n’ is estimated from linear regression of log 
(Mt/M) vs log t. If n = 0.45, it indicates Fickian diffusion; 
n<0.45≤0.89 indicates non fickian diffusion. Nonfickian diffusion 
involves a combination of both diffusion and erosion controlled 
release rate [45]. 
Fourier transform infrared spectroscopy (FTIR) 
FTIR spectra of pure drug, the physical mixture of niosomes, 
niososme pellets and niosomal in situ gel were evaluated (fig. 7-10). 
The FTIR study for the pure drug was carried out and the observed 
peaks were noted. From fig. 10, it was found that following were the 
peaks of the PSP present in the IR graph of the standard and this 
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confirms the purity of the drug. The peaks were observed at 715.5, 
892.8, 984.5, 1113.7, 1245.8, 1441.5, 1656.5, 1715.4, 2200.4, 2870.5, 
2937.06 and 3327.6 cm-1 which corresponded to =C-H out of plane 
bending, C-H aromatic out of plane bending, C-H stretching of alkyl 
substituted alkenes, C-H in-plane bending, C-O stretching, C=C aromatic 
stretching, C=C aromatic stretching, C=O ester stretching, Weak 




-symmetrical stretching, C-H aromatic stretching and 
O-H (free) alcoholic stretching respectively [46]. An overlay of all the 
spectra confirmed that all the peaks of the drug were retained in physical 
mixture and formulation as in pure drug which indicates drug and 
excipients were found to be compatible with each other. 
 














R R R R R n K  Min 
CS1 0.6148 0.9860 0.9877 0.9286 0.9987 0.4034 13.37 KP 112.8 
CS2 0.6615 0.9251 0.9646 0.8872 0.9526 0.5329 4.8165 M 271.9 
CS3 0.6229 0.9635 0.9817 0.9027 0.9820 0.4598 7.8542 KP 201.2 
CS4 0.5982 0.9818 0.9726 0.9250 0.9832 0.4718 8.3280 KP 155.2 
CS5 0.8932 0.9926 0.9849 0.9742 0.9866 0.6975 2.0973 FO 307.9 
CS6 0.8892 0.8520 0.9785 0.9333 0.9867 0.6135 3.3073 KP 218.1 
CS7 0.6320 0.8788 0.9653 0.8419 0.9836 0.4461 6.6215 KP 347.1 
CS8 0.6321 0.7365 0.8837 0.5983 0.9683 0.3460 11.909 KP 345.8 
CS9 0.7173 0.9369 0.9842 0.8888 0.9891 0.4683 5.5747 KP 379.7 
CS10 0.4564 0.8718 0.9504 0.7877 0.9860 0.3827 9.1718 KP 390.7 
CS11 0.5505 0.8696 0.9561 0.8192 0.9815 0.4330 7.6207 KP 299.5 
CS12 0.2242 0.9414 0.9506 0.8244 0.9946 0.3199 19.98 KP 110.4 
CS13 0.6615 0.9251 0.9646 0.8872 0.9526 0.5329 4.8165 KP 271.9 
CS14 0.1567 0.7936 0.8777 0.6439 0.9339 0.3713 11.318 KP 266 
CS15 0.4219 0.7193 0.8344 0.5055 0.9733 0.2875 15.69 KP 370.8 
CS16 0.6864 0.9312 0.9800 0.8766 0.9834 0.4759 5.3902 KP 435.2 
CS17 0.6671 0.8889 0.9826 0.8347 0.9935 0.4352 5.846 KP 491.9 
 
 
Fig. 7: FTIR spectra of PSP 
 
 
Fig. 8: Overlay of drug, physical mixture of niosomes and noisome pellets 
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Fig. 9: Overlay of drug and physical mixture 
 
 




Fig. 11: DSC spectra of PSP 
 
 
Fig. 12: Overlay of drug, the physical mixture of niosomes, and noisome pellets 
Desai et al. 




Fig. 13: Overlay of drug, physical mixture of niosomes, niosome pellets and niosomal in-situ gel 
 
 
Fig. 14: Overlay of drug, physical mixture of niosomes, niosome pellets, niosomal in-situ gel and synthesized bioadhesive polymer 
 
DSC of the drug was performed to evaluate the thermal profile of the 
drug (fig. 11). The onset of the peak observed at 80 ⁰C represented 
the peak of evaporation of water molecules due to heat. A sharp 
endothermic peak was observed at 220 ⁰C indicating the melting 
point of PSP (reported value 216 ⁰C). PSP crystals exhibit an 
endothermic peak at 320 °C due to decomposition of PSP. The DSC 
thermograms of pure drug, physical mixture of niosomes, niososme 
pellets and niosomal in situ gel along with synthesized polymer 
were obtained (fig. 12, 13 and 14). The peaks observed between 50-
60 ⁰C indicated melting points of maximum excipients used in the 
formulation like span 60, P407 and P188 [47,48]. The cholesterol 
has the melting point of 148 ⁰C which was shifted to 120 ⁰C due to 
evaporation of water absorbed by the poloxamer during formulation 
of in situ gel. The broad peak observed at 240 ⁰C indicates the 
melting point of synthesized bioadhesive polymer and drug. The 
absence of PSP peak on this thermogram has been taken to 
represent the only evidence of PSP amorphization. The physical 
state of the drug inside the carrier system is important because it 
can affect the in vitro and in vivo
 It was stated by Nasr 
 drug release [49]. The PSP peak was 
absent in the thermogram of niosomes. This situation shows that 
PSP was in amorphous structure and molecularly dispersed in 
niosomes as emphasized by Dong Y et al.2005. The amorphous PSP 
may be favorable due to the enhanced solubility of active agent [50]. 
et al.
Optical microscopy 
 2008 that absence of drug’s crystalline 
melting peak after niosomal encapsulation shows the high 
interaction between drug and surfactant bilayers of niosomes. This 
also explains the high entrapment of PSP into niosomes. In 
accordance with this, the entrapment of an active agent in niosomes 
was high in prepared formulations. 
 
 
Fig. 15: Optical microscopic image of niosomes 
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The niosomes were observed under the digital motic microscope 
(fig. 15). Vesicle size of niosomes was found to be in 0.2-0.5 μm 
range. The vesicles were circular in shape with uniform vesicle size 
distribution.
 
Vesicle size distribution 
 
Fig. 16: Vesicle size distribution of pure drug 
 
Vesicle size of pure drug and vesicle size of niosomal dispersion 
was measured by Nanophox NX0088 (fig. 16 and 17). Vesicle size 
of the pure drug was found to be 2002 nm which was reduced to 
465 nm for niosomal dispersion. Thus the particle size was 
reduced by 4 times making the formulation feasible for ocular 
use to enhance their penetration through different biological 
barriers of the eye. According to previous studies of 
ophthalmological applications, the size of complex drug particles 
should be less than 10 µm to avoid a foreign body sensation after 
administration [51]. Especially for ocular drug delivery, larger 
sized particles (>1 µm) may potentially cause ocular irritation 
[52]. In the ophthalmic field, particles of size range 10 to 1000 
nm allow for the improved topical passage of large molecules 
through the barriers of the ocular system [53]. Based on these 
results, delivery of ocular therapeutics via niosomes can be used 
to reduce the sensation and irritation of the eye. 
 
 
Fig. 17: Vesicle size distribution of niosomal dispersion 
 
Zeta potential determination 
 
Fig. 18: Zeta potential of niosomal formulation 
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The zeta potential for niosomal formulation was measured by 
zetasizer. It has long been recognized that the zeta potential is a very 
good index of the magnitude of the interaction between colloidal 
particles. Dissociation of acidic groups on the surface of a particle 
will give rise to a negatively charged surface. The magnitude of the 
surface charge depends on the acidic or basic strength of the surface 
groups and on the pH of the solution. The zeta potential of the 
noisome under study was found to be-44 mV (fig. 18). The negative 
charge is contributed by the negatively charged sulfonate groups 
present in span 60. The presence of a net charge, whether negative 
or positive, can increase water uptake within the double layer. It 
implies that equal molarity of nonionic surfactant and chol can make 
the membrane compact and well organized [54]. The magnitude of 
the zeta potential gives an indication of the potential stability of the 
colloidal system. If all the particles in suspension have a large 
negative or positive zeta potential, then they will tend to repel each 
other and there will be no tendency for the particles to come 
together. However, if the particles have low zeta potential values 
then there will be no force to prevent the particles from coming 
together and flocculating. The general dividing line between stable 
and unstable dispersions is generally taken at either+30 or-30 mV. 
Particles with zeta potentials more positive than+30 mV or more 
negative than-30 mV are normally considered stable. Thus it 
indicates that the formulation is stable and particle size will not 
increase due to aggregation or coagulation even after the 
formulation is kept for a long period of time. 
  
PDI 
Table 10: PDI of pure drug and niosomal formulation 
S. No. Sample name PDI* 
1. Pure drug 0.095±0.003 
2. Niosomal Formulation 0.284±0.026 
*(mean±SD, n=3) 
 
PDI values were calculated from vesicle size distribution data. The PDI 
value of formulation was found to be in the 0.284 which was found to 
be in the standard range i.e. less than 1 indicating that the formulation 
is monodisperse (table 10). The quality and uniformity of the 
dispersed systems are expressed with the PDI values. The values less 
than 0.7 are considered as suitable measurements. The low PDI values 
demonstrated the narrow size distribution and uniformity of the 
niosomal suspension [55]. Homogeneity of niosomal dispersions was 
indicated by the PDI values. 
TEM analysis 
Morphological characteristics of niosomal formulations were further 
confirmed by TEM analysis. TEM photomicrograph of (CS17) niosomal 
formulation at 40,000x and 45,000x (fig. 19) magnification revealed the 
spherical shape and morphology of the niosomes. Further, it was 
observed from the TEM images that niosomes are with hollow vesicular 
structure. The vesicle size (432 nm) observed in TEM was found to 
coincide with the value obtained by vesicle size determination thus 
confirming the size of vesicles to be in the colloidal range. 
In situ gel preparation 
Preliminary batches were prepared by varying the concentrations of 
P407 and P188 indifferent ratios and evaluated for gelation 
temperature (table 11). The concentration of P407 was varied 
from 10 to23% w/v whereas the concentration of P188 was 
varied from 10-30% w/v. While defining the ratios, care was 
taken that the total poloxamer concentration should not exceed 
40%w/v. The formulations containing only P407 showed higher 
sol-gel transition temperatures than the gel bases containing 
P188 in combination with it. The sol-gel transition temperature 
increased when the P407 concentration was decreased. This 
observation was in accordance with the data available in the 
literature [56]. When the mixtures were compared according to 
the ratio of P407/P188, it was observed that the w/w percent 
ratio of P407/P188 was important to reach the desirable 
gelation temperature and the result was compatible with the 
literature [57, 58].  
It was found that with the increase in the concentration of P188, the 
gelation temperature decreased significantly (p<0.05) and found to 
be equivalent to the physiological temperature that is 36-37⁰C. 
Gelation temperatures for P188 and P407 gels were observed for the 
different concentration range of polymer, and it was found that the 
gelation temperature of formulation decreased with increasing 
concentration of polymer. As the concentration of polymer 
increases, the gel structure becomes more closely packed with the 
arrangement in the lattice pattern [59]. 
 
  
Fig. 19: TEM images of optimized niosomal batch (CS17) 
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Evaluation of in situ gel 
Preliminary batches of in situ gel 
Table 11: Formulation batches of in situ gel along with gelation time, gel capacity and gel temperature 
Batch code P407 
(%w/v) 
P188 (%w/v) Gelation temperature ( °C) Gel capacity* Gelation time (min) 
G1 20 - >60 - - 
G2 18 - >60 - - 
G3 16 - >60 - - 
G4 21 - >60 - - 
G5 22 - >60 - - 
G6 23 - >60 - - 
G7 20 14 >60 - - 
G8 20 15 >60 - - 
G9 20 16 >60 - - 
G10 23 14 >60 - - 
G11 22 15 >60 - - 
G12 21 16 >60 - - 
G13 15 15 >60 - - 
G14 20 10 >56 - - 
G15 17 17 >60 - - 
G16 10 11 >57 + - 
G17 11 10 >57 + - 
G18 11 11 >57 + - 
G19 10 12 >52 - - 
G20 12 20 >52 - - 
G21 12 12 >52 - - 
G22 20 13 48-52 - - 
G23 13 20 48-52 - - 
G24 13 13 48-52 - - 
G25 10 15 43 + - 
G26 15 20 43 - - 
G27 15 15 42 - <1 
G28 10 16 43 + <1 
G29 17 10 42 + <1 
G30 17 17 43 ++ <1 
G31 10 18 42 + <1 
G32 18 20 42 ++ <1 
G33 20 18 40 ++ <1 
G34 10 25 37-38 +++ <1 
G35 10 27 37-38 +++ <1 
G36 10 30 36-37 +++ <1 
*(–): The solutions which did not undergo a phase transition at all. (+): The solutions which exhibited a phase transition only after 60 s. and the 
formed gels which collapsed within 1-2 h. (++): The solutions which formed the gels after 60 s. however, the gels formed did not remain stable for 
more than 3 h. (+++): The solutions which exhibited phase transition within 60 s and the gels so formed remained stable for more than 7-8 h. 
 
Evaluation parameters of in situ gel 
 
Table 12: Evaluation results of shortlisted formulations 
Formulations G34 (A) G35 (B) G36 (C) 
Appearance Translucent Translucent Translucent 
pH* 6.8±0.1 6.5±0.1 6.7±0.1 
Drug content (%)* 88.45±0.37 91.37±0.26 86.13±0.15 
Gelation temperature ( °C)* 37.7±0.5 37.2±0.5 36.9±0.5 
Gel strength (s)* 29±0.36 32±0.42 35±0.18 
Gelation time (min) <1 <1 <1 
Mucoadhesive strength (dynes/cm2 1837±0.35 )* 2043±0.26 2465±0.14 
Spreadability (cm)* 2.3±0.33 2.1±0.52 1.8±0.08 
*(mean±SD, n=3) 
 
The appearance of the formulation was translucent since niosomal 
pellets equivalent to drug dose were introduced into the gel 
formulation (table 12). The pH of the solution was found to be in the 
range of 6.5 to 6.8 since the pH of the formulation was maintained 
by addition of 0.1 M NaOH. The effect of polymer concentration on 
drug content was negligible because the drug was incorporated into 
niosomes and the drug was not directly dissolved into the gel 
formulation. Thus, DC was affected by niosomal formulation 
parameters and not by gel formulation parameters. With the 
increase in the concentration of P188, the gelation temperature was 
decreased and thus the optimum temperature of 37.2±0.2 ⁰C was 
obtained. Gel strength is the indication of the viscosity of the gel 
formulation. It was observed that with the increase in polymer 
concentration, gel strength was also increased. The mucoadhesive 
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strength limits the total clearance of drug from the ocular surface. 
Defining the mucoadhesive characteristics is of great importance 
when prolonged residence time and a decreased leakage of the 
formulation with the mucosal secretion are required [56]. The 
bioadhesive strength was not significantly affected by polymer 
concentration because the amount of addition of synthesized 
bioadhesive polymer was constant in all the three formulations. The 
bioadhesive strength of formulation was increased with increase in 
the concentration of polymer forming in situ gel formulation. In the 
literature, it was shown that P407 increased the mucoadhesive force 
of the formulation. It was also presented that the formulation 
prepared with the mixture of P407/P188 increased the 
bioavailability by preventing the migration of the formulation from 
the mucosal tissue [58]. This was in accordance with our data and 
the studies on the mucoadhesive property of poloxamers. The 
spreadability of the gel formulation was measured by texture 
analyzer. It was found that with the increase in polymer 
concentrations, the spreadability decreased significantly (p<0.05) 
due to the increase in viscosity of the formulation. It has been 
observed that increasing the concentration of any of the gelling 
agents was always associated with a decrease in the spreadability 
[60]. One of the criteria for a gel to meet the ideal quality is that it 
should possess good spreadability. It is the term expressed to denote 
the extent of area, to which gel readily spreads on application site. 
Lesser the time is taken for separation of two slides, better the 
spreadability. The gelling capacity of the formulation was measured 
on the basis of gelation time and time for which the gel remains to 
hold its solid state. It was observed that with significant (p<0.05) 
increase in P188 concentration (above 20% w/v), the gelling 
capacity improved thus forming within 60 s and holding its state for 
more than 7-8 h. 
Viscosity measurements 
The viscosity of the optimized formulation was measured at a 
different temperature from 25 ⁰C to 40 ⁰C (fig. 20). It was observed 
that the viscosity of gel was suddenly increased between 
temperature 35-37 ⁰C which indicated sol to gel transformation. The 
viscosity of gel formulation was found to be in the range of 800-900 
cps below 35 ⁰C which increased to about 4000-5000 cps above 35 
⁰C indicating gelation temperatures. The increase in the 




Fig. 20: Effect of temperature on viscosity of in situ gel data expressed mean±SD (n=3) 
 
 
Fig. 21: Comparison of viscosity change with change in shear rate at 25⁰C for different formulations data expressed mean±SD (n=3) 
 
All the formulations showed pseudoplastic rheological flow after 
studying at various temperatures, as evidenced by shear thinning 
and increase in shear stress with increased angular velocity. It was 
found that the rheological parameter was directly dependent on 
polymer concentration of formulation. At 25 ⁰C, all formulations 
were having low viscosity (fig. 21) and at 37 ⁰C, the formulations 
showed high viscosity (fig. 22). This indicates conversion of these 
formulations from sol to gel. It was also observed that viscosity of all 
the formulations was decreasing with the increase in shear rate. The 
non-newtonian formulations with pseudoplastic properties can 
acquire a viscosity decrease with increasing shear rate, creating 
blinking and ocular movement. Pseudoplasticity is thus interesting 
because it offers significantly less resistance to blinking and shows 
much greater acceptance than viscous newtonian formulations [61]. 
In vitro drug diffusion study 
The in vitro drug release profile of gel formulations was calculated 
by PCP disso software where the percent drug release along with 
dissolution kinetics and best fit model was found out. T90 value was 
found out using this PCP disso V3 software and comparison was 
done on its basis (fig. 23). The apparent diffusion coefficient values 
are given in table 12. It was observed that the diffusion coefficient 
for optimized formulation (1.998 x 10-5 cms-1) was higher as 
compared to the pure drug (0.710 x 10-5 cms-1) and marketed 
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formulation (0.865 x 10-5 cms-1
 
Fig. 22: Comparison of viscosity change with change in shear rate at 37⁰C for different formulations data expressed mean±SD (n=3) 
) thus proving increased permeability 
of drug through the membrane (table 13). These results can be 
attributed to the presence of bioadhesive polymer which retains the 
formulation in contact with the eye for a long period of time. 
 
 
The presence of polymers in in situ gel (P188 and P407) in lower 
concentrations acts as penetration enhancers and thus helps in 
penetration of PSP through the membrane. T90 value is the time at 
which 90% of the drug is released (table 14). A, B and C batch 
exhibited 90 value of 523 min (8 h and 43 min), 596 min(9 h 56 min) 
and 555 min (9 h 15 min) respectively. The release kinetics 
indicated that it followed zero order which means drug release does 
not depend on initial concentration.  
The B batch (P407:P188-1:2.7) was found to be the optimized batch 
with maximum t90 value thus sustaining the action for a long period 
of time. The marketed formulation and the pure drug showed 20-
23% drug diffusion in 6 h whereas the drug released by niosomal 
formulation was found to be in the range of 45-50 % in 6 h. Thus the 
amount of drug diffused was increased by niosomal in situ gel 
formulation. O. Inal et al. 2013 observed that the presence of P188 
polymer increased the release of meloxicam due to the change in the 
ratio of Poly Propylene oxide/Poly Ethylene Oxide (PPO/PEO) units 
in the polymer. Comparably shorter chain and low PPO/PEO molar 
ratio of hydrophilic P188 tend to disrupt the hydration shells around 
the hydrophobic portion of P407 molecules, which resulted as the 
high degree of water molecules around the PPO units. During 
gelation, those ordered water molecules had to be squeezed out into 
the bulk solution. Therefore, an increase in temperature required to 
promote the hydroscopic interaction between poloxamer micelles 
[62].  
Thus, the gel prepared with P188 has more tendencies to erode. 
As seen in fig. 23
 
Fig. 23: In vitro drug release profile of in situ niosomal batches data expressed mean±SD (n=3) 
 
Table 13: Amount of drug released in 6 h and apparent diffusion coefficient of different batches 
, formulations including P407:P188 
combination (A, B, C) showed higher erosion profiles than the 
others probably due to the decrease in PPO/PEO molar ratio of 
polymer in the gel. 
  
S. No. Batch Amount of drug diffused in 6 h Apparent diffusion coefficient (cm s* -1)* 
1. A 48.55±0.12 1.853* 10-5 






Pure drug 19.52±0.48 0.710*10
5. 
-5 
Marketed formulation 22.64±0.59 0.865*10-5 
*(mean±SD, n=3) 
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Korsmeyer–Peppas model Best fit 
kinetic model 
t90% 
R R R R R N K  Min 
A 0.9146 0.883 0.892 0.902 0.8526 0.4819 2.7082 ZO 523.4 
B 0.9777 0.946 0.888 0.959 0.9728 0.9384 0.2028 ZO 596.1 
C 0.9631 0.928 0.904 0.944 0.9353 0.6425 1.0740 ZO 555.6 
 
Ex vivo drug release studies 
 
Fig. 24: Ex vivo drug diffusion of optimized formulation data expressed mean±SD (n=3) 
 
The ex vivo drug diffusion study of optimized formulation showed 
that 90% of drug release was obtained in 10 h providing sustained 
effect (fig. 24). It is clear that a significantly higher amount 
(p < 0.05) of PSP permeated from the optimized formulation as 
compared to the marketed formulation. It is clear that niosomes 
prepared using Span 60 showed the more amount of PSP 
permeated, this might be attributed to the transition temperature 
of the used surfactant, where the high transition temperature of 
Span 60 made the niosomes in a more packed ordered gel state at 
the specified permeation temperature (37   °C) as studied by Vora 
et al., 1998. 
In vivo draize eye irritation test 
The marketed formulation showed just 20% drug 
release after 6 h which may be due to its larger molecule weight 
and thus large molecule size which indicates there may be a 
problem in the conjunctival absorption of the drug. Thus this 
problem was overcome by entrapment of PSP in niosomal in situ 
gel formulation. The size of vesicle was reduced due to its 
incorporation into niosomes and the release was sustained by in 
situ gel formulation. 
Pharmacodynamic study 
Primary skin irritation test 
The PII of the test sample was calculated to be 0.00;no irritation was 
observed on the skin of the rabbits/rats. The scores for erythema 
and edema were summed for intact and abraded skin for rabbits at 
24 and 72 h, PII was calculated. Based on the sum of the scored 
reactions divided by 32 (two scoring intervals multiplied by two test 
parameters multiplied by 8 animals). PII: 0/32 = 0.00. Under the 
conditions of this test, the test sample would not be considered a 
primary skin irritant since the PII was less than 5.00.  
The possibility of eye irritation due to niosomal in situ gel 
administration was evaluated in rabbits. The rabbits were observed 
for ocular lesions, and no symptoms of ocular irritation such as 
redness, tearing, inflammation, or swelling were observed after 
niosomal in situ gel administration. No ophthalmic damage or 
abnormal clinical signs to the cornea, iris or conjunctivae were 
visible. Thus, the developed ocular drug delivery systems are 
apparently free from any ocular irritation potential and can be safely 
administered to humans. The scores were calculated according to 
Draize scale. 
Pharmacokinetic study 
The aqueous humor concentration (mean±SD) time profiles of 
prednisolone sodium phosphate following ocular instillation of 
optimized niosomal in situ gel (B) and the drug solution in rabbits 
are depicted in fig. 25. The differences between the estimated drug 
pharmacokinetic parameters (Cmax, Tmax, and MRT (0–8 h) of the 
two treatments are illustrated in table 15. The mean (±SD) Cmax of 
the drug solution and that of the optimized formulation (B) were 
found to be equivalent. The delay in the median Tmax (from 1 to 2 
h), as well as the prolongation in the MRT (0–8 h) from 3.583±0.526 
to 5.349±0.035 h for the drug solution and the optimized 
formulation respectively, could indicate the sustained-release 
characteristics of the latter. Based on the calculated AUC(0–8)
In order to ensure the sterility of the finished product, the final 
formulation (B) was subjected to the sterility test. The formulation 
sterilized by membrane filtration method and incubated with 
different culture media like soybean casein digest medium; fluid 
thioglycate medium etc., for a period of 14 d of incubation did not 
show growth of the organism on the culture medium. This indicated 
that the formulation was sterile. 
 value, 
the increase in the ocular bioavailability was found to be 1.754-fold. 
The drug penetration enhancement following the instillation of the 
optimized formulation could be attributed to the presence of 
surfactant (span 60) in niosomal formulation which also acts as 
penetration enhancer. In addition to this, PSP being hydrophilic in 
nature can easily pass the epithelial barrier and thus contribute to 
increased penetration.  
The bioadhesive synthesized polymer macromolecular hydrocolloids 
have numerous hydrophilic functional groups (carboxylic acid). The 
cornea and conjunctiva have a negative charge where these 
mucoadhesive polymers may interact intimately with these 
extraocular structures [25], would increase the concentration and 
residence time of the associated drug. The elevated PSP levels in the 
cornea and aqueous humor following the administration of PSP-Gel 
might be due to the increase in the amount of PSP dissolved in the 
precorneal area leading to the high concentration gradient, favoring 
good permeation, together with higher contact time with the corneal 
area [63]. 
Sterility test 
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Fig. 25: Aqueous humor concentration-time profiles of PSP following ocular instillation of the drug solution and optimized B formulation 
to rabbits data expressed mean±SD (n=3) 
 
Table 15: The pharmacokinetic parameters of PSP following ocular instillation of the drug solution and optimized formulation B to 
rabbits 










Pure drug solution 1.573±0.345 1 3.75225±0.254 3.583±0.526 - 




Accelerated stability study 
Table 16: Stability testing by appearance, percent drug content determination and gelation temperature 
Time 
period 




Initial Translucent 91.36±0.36 37.2±0.23 
After 3 mo Translucent, little gel formation at the base which can be 
converted into sol after shaking 
90.53±0.27 37.0±0.41 
After 6 mo 88.45±0.47 37.0±0.05 
*(mean±SD, n=3) 
 
The results obtained show that all the formulations were found to 
contain almost same amount of drug after 6 mo. There was a little 
decrease in percent drug content but it was less than 5% for each 
formulation after 6 mo. The results obtained showed little decrease 
in the gelation temperature of the formulation with the increase in 
time but that was so less that it can be neglected (table 16). 
 
Long term stability study 
Table 17: Stability testing by appearance, percent drug content determination and gelation temperature 
Time period Appearance Percent drug content of optimized formulation Gelation temperature (⁰C)* * 
Initial Translucent 91.36±0.36 37.2±0.23 
After 3 mo Translucent and stable 89.53±0.27 37.1±0.41 
*(mean±SD, n=3) 
 
The results obtained showed that all the formulations were found to 
contain almost same amount of the drug after 3 mo. So it can be 
concluded that there wasn't any drug loss from formulation during 
storage. The results obtained showed there wasn't any significant 
change in the gelation temperature of the formulations after 3 mo. 
So, it can be predicted that the formulation would be stable during 
storage (table 17). 
CONCLUSION 
Different approaches have been used till now in order to overcome 
the drawbacks related to conventional ocular delivery systems and 
to improve patient compliance without losing the therapeutic 
activity of the drug. Niosomal in situ gel proved to be one of the 
successful approaches to accomplish the goals successfully. 
Niosomes optimal batch (CS17) was able to entrap PSP where 
entrapment efficiency was found to be 83.4±0.22%. As a result, the 
optimal formula was further incorporated into on situ gel with 
desirable mucoadhesive behavior essential to achieve increased 
retention at the target site. The formula exhibited significant 
permeation with almost 2.5 fold increased flux and sustained for 
longer periods (t90= 10 h) compared to the pure drug and marketed 
formulation at the same dose level. The pharmacokinetic study in 
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rabbits proved that the total concentration of PSP in aqueous humor 
was higher as compared to that of pure drug solution. The mean 
residence time and the shift in tmax value indicated sustained 
release of the drug. Thus niosomal in situ system proved to be a very 
useful system for ocular drug delivery with promising results. 
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